MEMC - GREAT Rome (Italy), 05/09/2015 - 09/09/2015 Topic: Cardiovascular / Non-CPR/Non-Resuscitation
J18
INFLUENCE OF METABOLIC SYNDROME ON ACUTE HEART FAILURE CLINICAL PRESENTATION
I. Potocnjak 1, S. Dokoza Teresak 1, B. Radulovic 2, M. Trbusic 1,3, G. Pregartner 4, V. Degoricija* 1,3, S. Frank* 5
1
University Hospital Center Sisters Of Charity, Zagreb, Croatia, 2 University Hospital Centre Zagreb, Zagreb, Croatia, 3 University Of Zagreb School Of Medicine, Zagreb, Croatia, 4 Medical University Of Graz, Institute For Medical Informatics, Statistics Und Documentation, Graz, Austria, 5 Medical University Of Graz, Institute Of Molecular Biology And Biochemistry, Center Of Molecular Medicine, Graz, Austria Background: Metabolic syndrome (MS) is important concomitant disease in acute heart failure (AHF) thus its effect on HF clinical presentation is crucial field of investigation. Various classifications of acute HF are utilized in intensive cardiac care units. The aim of this study was to investigate influence of MS on clinical presentation of AHF defined by European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure. Methods: Study was performed as observational, prospective study on hospitalised AHF patients (pts.). Subjects were recruited from the Emergency Department, from November 2013 to February 2015. Participants were divided in two groups depending on coexistence of MS and clinical presentation of AHF. Pts. were compared according to clinical presentation of AHF, including the following: worsening of decompensated chronic HF, pulmonary oedema, hypertensive HF, cardiogenic shock, isolated right HF and acute coronary syndrome (ACS) and HF. Pts. were treated by standard protocol for AHF treatment by ESC Guidelines. Study was approved by local Ethics committee and performed according to Good Clinical Practice and Helsinki Declaration principles. Results: Complete analysis included data for 152 pts. 55.92% of pts. with AHF had MS. In total 51.3% of pts. had worsening of chronic HF, 15.1% had ACS and HF, 14.5% had hypertensive AHF, 13.2% had pulmonary edema, 4.6% had isolated right side HF, and 1.3% had cardiogenic shock. There was no statistically significant difference between groups with and without MS (p=0.178). According to time of onset 69.1% of pts. had worsening of chronic HF, and rest of them de novo, as well without difference in MS comorbidity (p=0.380). Our study showed that ejection fraction was reduced for 57.6%, without difference in coexistence in MS comorbidity (p=0.866). Conclusions: Results of this study showed that MS is serious concomitant parameter in AHF pts. However, it was not proven that it can influence clinical presentation of AHF. Pts. suffering from AHF should be treated individualy and dependently on their clinical presentation. MS as frequent disease has to be accentuated, diagnosed and treated. *equally contributing senior authors and project leaders